免疫检查点抑制剂常见免疫相关不良反应及其管理

国际肿瘤学杂志››2021,Vol. 48››Issue (2): 105-108.doi:10.3760/cma.j.cn371439-20200828-00020

免疫检查点抑制剂常见免疫相关不良反应及其管理

李慧, 杨宇()

哈尔滨医科大学附属第二医院肿瘤内科 150000

收稿日期:2020-08-28修回日期:2020-09-20出版日期:2021-02-08发布日期:2021-03-11
通讯作者:杨宇 E-mail:yangyu13836125585@163.com

Common immune-related adverse reactions of immune checkpoint inhibitors and their management

Li Hui, Yang Yu()

Department of Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin 150000, China

Received:2020-08-28Revised:2020-09-20Online:2021-02-08Published:2021-03-11
Contact:Yang Yu E-mail:yangyu13836125585@163.com

摘要/Abstract

摘要：

目前临床上免疫检查点抑制剂(ICI)应用广泛,常见的不良反应包括皮肤、胃肠道、内分泌和肝脏不良反应,肺脏和心脏不良反应相对较少,但可能致命。类固醇全身治疗是对抗免疫治疗相关不良反应(irAE)的主要治疗手段,如对类固醇治疗没有反应,则需要考虑使用免疫调节剂。掌握irAE的发生率、发病机制、常见类型及其治疗策略,可为ICI在临床上的安全应用提供理论依据。

关键词:肿瘤,免疫检查点抑制剂,免疫治疗相关不良反应,治疗策略

Abstract:

At present, immune checkpoint inhibitors (ICIs) are widely used in clinical, and the common adverse reactions include adverse reactions of skin, gastrointestinal tract, endocrine and liver. Adverse reactions to the lungs and heart are relatively rare, but can be fatal. Systemic steroid therapy is the main treatment for immune related adverse events (irAEs). If there is no response to steroid therapy, an immunomodulator may be considered. Understanding the incidence, pathogenesis, common types and treatment strategies of irAEs can provide theoretical basis for the safe application of ICIs in clinical practice.

Key words:Neoplasms,Immune checkpoint inhibitor,Immune related adverse events,Treatment strategy

李慧, 杨宇. 免疫检查点抑制剂常见免疫相关不良反应及其管理[J]. 国际肿瘤学杂志, 2021, 48(2): 105-108.

Li Hui, Yang Yu. Common immune-related adverse reactions of immune checkpoint inhibitors and their management[J]. Journal of International Oncology, 2021, 48(2): 105-108.

参考文献17

[1]	Inno A, Metro G, Bironzo P, et al. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity[J]. Tumori, 2017,103(5):405-421. DOI: 10.5301/tj.5000625. doi:10.5301/tj.5000625pmid:28497847
[2]	Zhou X, Yao Z, Yang H, et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis[J]. BMC Med, 2020,18(1):87. DOI: 10.1186/s12916-020-01549-2. doi:10.1186/s12916-020-01549-2pmid:32306958
[3]	Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade[J]. Cancer, 2017,123(S11):2143-2153. DOI: 10.1002/cncr.30444. doi:10.1002/cncr.30444pmid:28543699
[4]	Kimbara S, Fujiwara Y, Iwama S, et al. Association of antithyroglo-bulin antibodies with the development of thyroid dysfunction induced by nivolumab[J]. Cancer Sci, 2018,109(11):3583-3590. DOI: 10.1111/cas.13800. doi:10.1111/cas.13800pmid:30230649
[5]	Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody[J]. Sci Transl Med, 2014,6(230):230ra45. DOI: 10.1126/scitranslmed.3008002. doi:10.1126/scitranslmed.3008002pmid:24695685
[6]	Baban B, Liu JY, Qin X, et al. Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153[J]. PLoS One, 2015,10(4):e0124059. DOI: 10.1371/journal.pone.0124059. doi:10.1371/journal.pone.0124059pmid:25902191
[7]	Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma[J]. J Clin Oncol, 2017,35(7):785-792. DOI: 10.1200/JCO.2015.66.1389. doi:10.1200/JCO.2015.66.1389pmid:28068177
[8]	Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor[J]. Eur J Cancer, 2016,60:12-25. DOI: 10.1016/j.ejca.2016.02.010. doi:10.1016/j.ejca.2016.02.010pmid:27043866
[9]	Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1[J]. Cancer Immunol Res, 2016,4(5):383-389. DOI: 10.1158/2326-6066.CIR-15-0123. doi:10.1158/2326-6066.CIR-15-0123pmid:26928461
[10]	Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes[J]. Clin Cancer Res, 2016,22(4):886-894. DOI: 10.1158/1078-0432.CCR-15-1136. doi:10.1158/1078-0432.CCR-15-1136pmid:26446948
[11]	Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events[J]. J Am Acad Dermatol, 2014,71(1):161-169. DOI: 10.1016/j.jaad.2014.02.035. doi:10.1016/j.jaad.2014.02.035
[12]	Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J]. Nat Rev Clin Oncol, 2016,13(8):473-486. DOI: 10.1038/nrclinonc.2016.58. doi:10.1038/nrclinonc.2016.58pmid:27141885
[13]	Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)[J]. Lancet, 2017,390(10105):1853-1862. DOI: 10. 1016/S0140-6736(17)31601-X. pmid:28822576
[14]	De Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients[J]. Cancer Immunol Res, 2017,5(4):312-318. DOI: 10.1158/2326-6066.CIR-16-0237. doi:10.1158/2326-6066.CIR-16-0237pmid:28246107
[15]	Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management[J]. ESMO Open, 2018,3(1):e000278. DOI: 10.1136/esmoopen-2017-000278. doi:10.1136/esmoopen-2017-000278pmid:29387476
[16]	Rajha E, Chaftari P, Kamal M, et al. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy[J]. Gastroenterol Rep (Oxf), 2019,8(1):25-30. DOI: 10.1093/gastro/goz065.
[17]	Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015,372(26):2521-2532. DOI: 10.1056/NEJMoa1503093. doi:10.1056/NEJMoa1503093pmid:25891173